Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of CHF 5993 in Japanese and Caucasian Healthy Subjects
NCT03859414Phase 1Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Mar 2019
- Primary completion
- Jul 2019
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium in asthma and chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Area Under the Curve at 48 hours and Maximum Concentration at 48 hours. Started Mar 2019; status: completed.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrronium
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03859414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03859414.